Tag: Afamitresgene autoleucel FDA approval

Home / Afamitresgene autoleucel FDA approval

Categories

The FDA has granted accelerated approval to afamitresgene autoleucel for the treatment of unresectable or metastatic synovial sarcoma

August 2024: The Food and Drug Administration has given accelerated approval to afamitresgene autoleucel (TECELRA, Adaptimmune, LLC), a genetically modified autologous T cell immunotherapy that target...
afamitresgene-autoleucel-fda-approval

Scan the code